Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
Millennium Pharmacon International Tbk
SDPC
Sector: Consumer Non-Cyclicals
Industry: Food & Staples Retailing
Sub Sector: Food & Staples Retailing
Sub Industry: Drug Retail & Distributors
Live quote
tidak tersedia
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
31
ROE
11,81%
ROA
1,86%
Book Value
260
Net Income
19,56 M
Total Sales
2,13 T
Total Assets
2,10 T
DER
5.34x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
8,78%
9,72%
1,86%
1,83%
1,02%
Tentang Perusahaan
PT Millennium Pharmacon International Tbk (the Company) was established on October 20th, 1952 under the name N.V. Perusahaan Dagang SOEDARPO CORPORATION. On July 29th, 1997, the Extraordinary Shareholders meeting held by the Company has approved the sale of assets and of the whole share participation on the Company in PT Praweda Ciptakarsa Informatika and PT Sumber Daya Praweda Informatika. In order to strengthen its equity and settle the foreign currently loan, the Company has conducted its first Right Issue and has submitted the registration statement on May 8th, 2000 to the Capital Advisory Board (BAPEPAM). The Company started its operations on October 20, 1952. The name was changed from previous name PT NVPD Soedarpo Corporation.
Produk & Lini Bisnis
The Company is engaged in distribution and trading of prescription medicine, non-prescription medicine and medical devices.
Dewan Direksi
AB
Ahmad Bin Abu Bakar
President Director
MF
Mohamad Fazly Bin Hassan
Director
Dewan Komisaris
JJ
Joefly Joesoef Bahroeny
President Commissioner/Ind
ZB
Zulkifli Bin Jafar
Commissioner
AB
Aman Bhakti Pulungan
Independent Commissioner
DI
Drs. Imam Fathorrahman, MM
Independent Commissioner
SA
Sarah Azreen Binti Abdul Samat
Independent Commissioner
Anak Usaha & Afiliasi
| Nama | Domisili | % |
|---|---|---|
| % |
Trend Keuangan (5 periode terakhir)
— hover bar untuk detail
Total Sales
Net Income (+)
Net Income (-)
2025 Q2
EPS 26
ROE 11,29%
2025 Q3
EPS 21
ROE 9,05%
2025 Q4
EPS 30
ROE 12,20%
2026 Q1
EPS 32
ROE 12,42%
2026 Q2
EPS 31
ROE 11,81%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
| Periode | Total Sales | Net Income | Total Assets | Total Equity | EPS | ROE | DER |
|---|---|---|---|---|---|---|---|
| 2026 Q2 | 2,13 T | 19,56 M | 2,10 T | 331,16 M | 31 | 11,81% | 5.34x |
| 2026 Q1 | 1,02 T | 10,10 M | 2,02 T | 325,53 M | 32 | 12,42% | 5.19x |
| 2025 Q4 | 4,11 T | 38,47 M | 1,96 T | 315,42 M | 30 | 12,20% | 5.22x |
| 2025 Q3 | 3,00 T | 20,39 M | 1,90 T | 300,35 M | 21 | 9,05% | 5.34x |
| 2025 Q2 | 1,94 T | 16,75 M | 1,89 T | 296,71 M | 26 | 11,29% | 5.36x |
History Harga Penutupan & Book Value
| Tahun | Qrt | Close Price (Rp) | Book Value (Rp) | ROA |
|---|---|---|---|---|
| 2026 | 2 | 178 | 260 | 1,86% |
| 2026 | 1 | 193 | 256 | 2,01% |
| 2025 | 4 | 155 | 248 | 1,96% |
| 2025 | 3 | 137 | 236 | 1,43% |
| 2025 | 2 | 127 | 233 | 1,78% |
Data diperbarui pada: 2026-05-12 11:52:21